Novartis Asks CHMP To Modify European Galvus Label To Recommend Lower Dose
Patients taking 50 mg dose of DPP-4 inhibitor had fewer liver enzyme elevations than those taking 100 mg, a profile Novartis wants to include in the label prior to EU launch.
Patients taking 50 mg dose of DPP-4 inhibitor had fewer liver enzyme elevations than those taking 100 mg, a profile Novartis wants to include in the label prior to EU launch.